Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Archimedes Raises £65 million for Leap to U.S.

This article was originally published in Start Up

Executive Summary

About a year after Novo A/S announced the launch of its Growth Equity Fund, the firm has found a home for its first significant investment, contributing £40 million of a £65 million ($100 million) round for privately-owned UK-based specialty pharma firm Archimedes Pharma. Participants describe this as the largest private European biopharma fundraising in the last 15 years.
Advertisement

Related Content

Can New Pain Drugs Break Through To A Growing Cancer Market and Beyond?
Can New Pain Drugs Break Through To A Growing Cancer Market and Beyond?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
European Specialty Pharma In Transition: Is A U.S. Presence Necessary?
Denmark's Symphogen Breaks European Private Funding Record With €100m Haul
ProStrakan In Buyers' Sights After Setbacks
Biopharma Quarterly Statistics Q1 2010
Ex-Shire Team Builds New Euro-Specialty Group
Investing Warburg Pincus Style

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091933

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel